[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Oklahoma State University Center for Health Sciences\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":72},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100642063","the-impacts-of-ashwagandha-supplementation-on-diurnal-cortisol-and-stress-among-women-100642063",false,"NCT07647081","The Impacts of Ashwagandha Supplementation on Diurnal Cortisol and Stress Among Women","Female Adversity and Biology: Stress Reduction","FAB:SR","Inclusion Criteria:\n\n1. Female, ages 18-45\n2. No hormonal birth control\n3. Identify as having a regular sleep schedule (eg. sleep by 1am and wake by 9am)\n4. Identify as having a regular menstrual period between 27-32 days apart on average\n5. PSS score of 14 (moderate stress) or greater\n6. No expected changes in stress levels over the next 3 months and agree to not initiate any new stress-reduction behaviors before study start or during the study\n\nExclusion Criteria:\n\n1. Diagnosed major depressive disorder or generalized anxiety disorder in the last 3 months, any liver, kidney, or thyroid disorder\u002Fdysfunction\u002Finjury, or diabetes\n2. Using any medication related to cortisol or HPA function such as corticosteroids, antidepressants, anti-psychotics, CNS-depressants (benzodiazepines, non-benzodiazepine sedatives, barbiturates, anti-convulsants, anesthetics), thyroid medications, diabetic medications, or immunosuppressants\n3. Taken any form of ashwagandha within the last 3 months\n4. Daily use of alcohol, nicotine, or other substances\n5. Who are pregnant, planning to become pregnant, breastfeeding, or have had a hysterectomy\n6. Abnormal liver function test value(s) at screening",true,"FEMALE","18 Years","45 Years",{"count":22,"type":23},30,"ESTIMATED","INTERVENTIONAL",[26],"NA","The purpose of this project is to better understand the role of ashwagandha on the stress response and wellbeing among healthy, stressed women.",[29],"Stress",[31,32,33,34,35],"stress","women","ashwagandha","cortisol","female","NOT_YET_RECRUITING","2026-06-09",{"date":39,"type":40},"2026-06-15","ACTUAL",{"date":42,"type":23},"2026-06",{"date":44,"type":23},"2027-05",{"name":46,"class":47},"Oklahoma State University Center for Health Sciences","OTHER",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":55,"minAge":19,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":24,"phases":59,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":4},"100584584","the-utility-of-osteopathic-manipulative-medicine-in-weaning-patients-from-the-ventilator-pilot-trial-100584584","NCT06891248","The Utility of Osteopathic Manipulative Medicine in Weaning Patients from the Ventilator Pilot Trial","The Utility of Osteopathic Manipulative Medicine in Weaning Patients from the Ventilator","Inclusion Criteria:\n\n1. Acute respiratory failure (hypoxic, hypercapnic, or neuromuscular)\n2. Not making satisfactory progress with weaning after being on the ventilator for more than 48 hours\n3. Clinical stability for pressure support trial with ventilator to monitor ventilation progression\n4. Pulmonology must be following the patient for standardized ventilator management approach and interventions as needed\n5. Medical power of attorney (POA) or legally authorized representative (LAR) who is able to consent subject for trial enrollment and treatment\n6. Patients who were not referred to the OMM service\n\nExclusion Criteria:\n\n1. Age less than 18 years old or more than 85 years old\n2. BMI\\>60\n3. Moderate\u002Fsevere neurological disease with expectation of non-progression off the ventilator or poor quality of life predicted (including end-stage dementia with the expectation of non-progression off ventilator, multiple sclerosis, ALS, anoxic brain injury, etc)\n4. Status epilepticus or EEG result pending\n5. Post-arrest hypothermia protocol\n6. Acute stroke\n7. Acute rib fractures preventing the implementation of the treatment protocol\n8. Acute spinal injury preventing the implementation of the treatment protocol\n9. Recent head injury requiring close clinical monitoring\n10. Ejection Fraction less than 15%\n11. Pleural effusion requiring procedural intervention or inhibiting ventilator progress\n12. Pericardial effusion or tamponade requiring procedural intervention or inhibiting ventilator progress\n13. ACLS\u002Fcardiac arrest within the past 72 hours\n14. Confirmed opioid overdose with positive urine drug screen and response to naloxone\n15. Patients who were referred to the OMM service","ALL","85 Years",{"count":58,"type":23},20,[26],"The objectives of this research are to determine the treatment effect size of OMM to wean patients off of the ventilator, determine the number of patients needed for a larger study (power), determine the willingness of patients\u002FPOAs to be recruited, identify the correct dosing of OMM and whether there are concerns for the safety of treatment, and determine whether the hypothesis is feasible for a larger study. The primary outcome measure is the duration of time until a subject is weaned off of mechanical ventilation using Osteopathic Manipulative Medicine (OMM). The secondary outcome measures (see the next section for further explanation) are to determine if OMM affects changes in morbidity and mortality, such as VBG\u002FABG, NIF, RSBI, P 0.1, FiO2, PEEP, mental status, hemodynamic stability (blood pressure), spontaneous TV, reintubation after extubation, and death.",[62,63],"Respiratory Failure","Osteopathy in Diseases Classified Elsewhere","2025-03-18",{"date":66,"type":40},"2025-03-24",{"date":68,"type":23},"2025-03-17",{"date":70,"type":23},"2025-06-08",{"name":46,"class":47},""]